CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking ...

The company announced the acquisition of 100% global ownership of its novel antibiotic Enmetazobactam, which was originally ...

Leveraging the power of Microsoft Cloud for health authority queries to create streamlined, efficient processes.

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...

Regulators block Duchenne muscular dystrophy treatment after fatal side-effects outweigh questionable efficacy ...

Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, BC / ACCESS Newswire / July 30, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfur ...

Following the FDA approval of linvoseltamab (Lynozyfic; Regeneron) for heavily pretreated multiple myeloma, Sundar Jagannath, MBBS, highlights its potential for earlier use, increased accessibility, ...

SOURCE: Biolog, Inc. The post Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence ...

These guidelines help ensure that products are fit for their intended use and comply with applicable regulatory standards.

New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company ...